Beijing Science Sun Pharmaceutical Co., Ltd. Share Price

Equities

300485

CNE100002110

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 20/06/2024 BST 5-day change 1st Jan Change
6.32 CNY +0.80% Intraday chart for Beijing Science Sun Pharmaceutical Co., Ltd. -1.86% -40.32%

Financials

Sales 2022 735M 101M 8B Sales 2023 477M 65.64M 5.19B Capitalization 5.1B 703M 55.58B
Net income 2022 205M 28.24M 2.23B Net income 2023 103M 14.19M 1.12B EV / Sales 2022 6.33 x
Net cash position 2022 1.12B 154M 12.22B Net cash position 2023 1.17B 162M 12.79B EV / Sales 2023 8.24 x
P/E ratio 2022
27.9 x
P/E ratio 2023
50.4 x
Employees -
Yield 2022
0.72%
Yield 2023
0.21%
Free-Float 41.18%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves Cash Dividend for 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. agreed to acquire 5.6664% stake in Suzhou Inhal Pharma Co., Ltd. from Ningbo Menovo Ruihe Equity Investment Partnership for CNY 10 million. CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for the Year 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd.(XSEC:300485) added to S&P Global BMI Index CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves Final Dividend for 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day+0.80%
1 week-1.86%
Current month-12.95%
1 month-16.18%
3 months-26.00%
6 months-39.05%
Current year-40.32%
More quotes
1 week
6.15
Extreme 6.15
6.57
1 month
6.06
Extreme 6.06
7.42
Current year
6.06
Extreme 6.06
10.74
1 year
6.06
Extreme 6.06
12.27
3 years
6.06
Extreme 6.06
18.75
5 years
6.06
Extreme 6.06
28.08
10 years
6.06
Extreme 6.06
44.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 04/07/01
Chief Administrative Officer 45 27/01/21
Chief Tech/Sci/R&D Officer 49 28/02/01
Members of the board TitleAgeSince
Director/Board Member 51 01-25
Director/Board Member 46 31/12/98
Chief Executive Officer 60 04/07/01
More insiders
Date Price Change Volume
21/06/24 6.32 +0.80% 2,286,539
20/06/24 6.27 -1.88% 2,874,060
19/06/24 6.39 -0.47% 1,711,300
18/06/24 6.42 +0.78% 2,135,700
17/06/24 6.37 -1.09% 1,769,900

End-of-day quote Shenzhen S.E., June 20, 2024

More quotes
Beijing Science Sun Pharmaceutical Co., LTD. is a China-based company principally engaged in research, manufacture and sales of biological and biochemical pharmaceuticals. The Company' products can be divided into cardiovascular series, immune regulation series, nervous system series and other natural or biotech pharmaceuticals. Its products include small capacity injection and freeze-dried powder injection.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300485 Stock